HC Wainwright & Co. Reiterates Buy on Arrowhead Pharma, Maintains $60 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Arrowhead Pharma, maintaining a price target of $60.
October 11, 2024 | 7:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Arrowhead Pharma, maintaining a price target of $60, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $60 price target by HC Wainwright & Co. suggests a positive outlook for Arrowhead Pharma. This can lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100